Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $69.90M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.07M
Average 0.16M
Income Statement
Follow revenue through to earnings.
Revenue
$7.95M
FY 2025 · Annual
+123.6% YoYOperating Income
-$20.27M
FY 2025 · Annual
Net Income
-$21.23M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6M | 3.55M | 7.95M |
| Cost of Revenue | 0 | 4.41M | 5.5M | 11.87M | 27.36K |
| Gross Profit | 0 | (4.41M) | 500.68K | (8.31M) | 7.92M |
| Gross Margin | — | — | 8.3% | -233.9% | 99.7% |
| Research & Development | 2.54M | 4.94M | 6.04M | 11.89M | 16.73M |
| Selling, General & Admin | 2.31M | 4.85M | 7.83M | 8.89M | 11.45M |
| Operating Expenses | 4.87M | 5.4M | 8.4M | 8.94M | 28.18M |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| EBITDA | (4.88M) | (9.26M) | (7.33M) | (17.2M) | (21.2M) |
| EBITDA Margin | — | — | -122.2% | -483.9% | -266.8% |
| Operating Income | (4.87M) | (9.81M) | (7.9M) | (17.25M) | (20.27M) |
| Operating Margin | — | — | -131.7% | -485.4% | -255.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (21.48K) | (2.43M) | 639.37K | 1.65M | (957.4K) |
| Income Before Tax | (4.89M) | (12.24M) | (7.26M) | (15.6M) | (21.22M) |
| Pre-Tax Margin | — | — | -121.0% | -439.0% | -267.1% |
| Income Tax Expense | 0 | 0 | 723.85K | (720.29K) | 3.09K |
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Net Margin | — | — | -133.1% | -418.7% | -267.1% |
| EPS (Basic) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| EPS (Diluted) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| 6.6M | 9.95M | 10.16M | 15.24M | 16.73M | |
| 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
COYA Earnings Waterfall · TTM
NASDAQ:COYA · Revenue to Net Income
Key Ratios
Analysis
$7.9M of revenue converted into -$21.1M of net income for the selected period. Gross margin is 98.6% and net margin is -1699.6%, showing how much revenue survives after costs and taxes. EPS is $-1.15, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 8-K | Current report | Oct 5, 2026 | |
| 8-K | Current report | Sep 15, 2026 |
How much revenue does COYA generate?
Coya Therapeutics, Inc. (COYA) reported $7.95M of revenue in fiscal 2025.
Is COYA profitable?
Coya Therapeutics, Inc. (COYA) reported -$21.23M of net income, with a net margin of -267.1%.
Continue the stock analysis
Jump to another research area for this company.